Back to results
US 2013/0273139 A1Published application
Transdermal delivery systems
AssigneeDurect Corporation
InventorsSu Il Yum, Sung Yun Kwon, Xiaoping Song, James E. Brown
Life of this patent
Estimating the term…
Abstract
Disclosed are bupivacaine transdermal delivery systems, and related methods.
Claims22
A pressure sensitive adhesive composition, capable of being incorporated into a transdermal delivery system, comprising:
- one or more rheology and surface energy modifying agents present in an amount effective to reduce a peel force of the transdermal delivery system by at least 10% compared to the peel force of the transdermal delivery system comprising a pressure sensitive adhesive composition that does not comprise the one or more rheology and surface energy modifying agents.
-8. (canceled)
A transdermal delivery system comprising:
- a backing layer, and
- a reservoir laminated to the backing layer that comprises bupivacaine;
- and
- wherein the reservoir is adapted to transdermally deliver the bupivacaine from the transdermal delivery system to a subject for a period such that the following mean plasma concentrations are achieved:
- a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0003 to about 0.7 cm2/L at about 12 hours after initiation of the transdermal delivery;
- and
- a mean plasma concentration, normalized to an initial loading of the transdermal delivery system, ranging from about 0.0014 to about 0.4 cm2/L at about 24 hours after initiation of the transdermal delivery.
4 more elements
(canceled)
A method comprising:
- applying to a transdermal delivery system that comprises bupivacaine;
- transdermally delivering the bupivacaine from the transdermal delivery system such that the following mean in vitro bupivacaine fluxes are achieved:
- a mean in vitro bupivacaine flux ranging from about 0.1 to about 8 microgram/cm2/hr at about 12 hours after initiation of the transdermal delivery;
- and
- a mean in vitro bupivacaine flux ranging from about 0.25 to about 6 microgram/cm2/hr at about 24 hours after initiation of the transdermal delivery.
2 more elements
Dependencies are inferred from the claim text.